Recurrent IDH mutations in high-grade meningioma

Neuro Oncol. 2020 Jul 7;22(7):1044-1045. doi: 10.1093/neuonc/noaa065.

Authors

Corey M Gill¹, Joshua Loewenstern¹, John W Rutland¹, Hanane Arib², Nancy Francoeur², Ying-Chih Wang², Nataly Fishman², Margaret Pain¹, Melissa Umphlett³, Yayoi Kinoshita³, Russell B McBride^{3

4}, Joshua Bederson¹, Michael Donovan³, Melissa Smith², Robert Sebra⁵, Raj K Shrivastava¹, Mary Fowkes³

Affiliations

¹ Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York.
² Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
³ Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
⁴ The Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York.
⁵ Sema4, A Mount Sinai venture, Stamford, Connecticut.

No abstract available

Publication types

Letter

MeSH terms

Brain Neoplasms*
Humans
Isocitrate Dehydrogenase / genetics*
Meningeal Neoplasms* / genetics
Meningioma* / genetics
Mutation

Substances

Isocitrate Dehydrogenase

Grants and funding

P30 CA013330/CA/NCI NIH HHS/United States